BlueWind Medical
BlueWind Medical is an innovative medical device company that aims to transform neuromodulation therapy. Founded in 2010 by the Rainbow Medical Group, BlueWind Medical has grown to an established company with diverse, creative and committed employees. BlueWind Medical has successfully completed or is nearing completion of several clinical studies with excellent results and is focused on bringing this breakthrough RENOVA iStim neuromodulation device for the treatment of Overactive Bladder to the market.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Clinical Services
- Market Focus:
- Internationally (various countries)
- Year Founded:
- 2010
About Us
- BlueWind Medical is transforming neuromodulation to deliver safe, targeted and accessible OAB therapy.
- The RENOVA iStim™ implant is miniature, wireless, battery-less and fully-featured.
- This is the future of neuromodulation, enabling wider therapy acceptance by both physicians and patients.
BlueWind Medical strives for the highest quality product and most advanced engineering and manufacturing processes. By placing patient needs first, we have created a versatile and effective platform that will transform neuromodulation as we know it.
Our Vision
To provide safe and effective peripheral neuromodulation solutions for patients suffering from neurological disorders.
Our Mission
To help patients around the world, initially focusing on tibial neuromodulation by treating pelvic floor disorders, including over-active bladder.
Promising Therapy for Overactive Bladder
In the pilot clinical study, 71% of patients implanted with the BlueWind Medical RENOVA™ iStim system experienced 50% or greater reduction in one or more OAB symptoms or a return to normal voiding at 6 months follow-up (1). BlueWind Medical is currently conducting OASIS, a pivotal IDE clinical trial, and has completed enrollment of 151 patients. BlueWind intends to submit 6-month and 12-month safety and efficacy data to the FDA in 2022.